PURPOSE: To evaluate the efficacy of @entity619 0.7mg intravitreal implant in @entity1 with @entity1103 . MATERIALS AND METHODS: Fourteen @entity1 ' charts with @entity1103 were retrospectively reviewed. The main outcome measures were best-corrected visual acuity (BCVA) and mean @entity989 ( @entity989 ). RESULTS: @entity1 ' mean age was 72.1  years old. Five @entity1 were @entity6 . All @entity1 had previously been treated with non-steroidal anti-inflammatory drops. Four @entity1 had received a previous treatment with intravitreal ranibizumab. The mean follow-up period was 8.7  months. Mean BCVA before intravitreal @entity619 was 0.72  logMAR. After injection, it improved to 0.50  at month 1, was 0.47  at month 3, and 0.60  logMAR at month 12. The pre-injection mean @entity989 was 598 m. It improved to 286 m at month 1, 338 m at month 3, and was 441 m at month 12. Eight @entity1 received 2  intravitreal injections of @entity619 . Five @entity1 presented with elevated intraocular pressure during follow-up, which was treated with drops. CONCLUSIONS: Intravitreal @entity619 injection improved visual acuity and macular thickness at month 1  and month 3  in @entity1 with @entity1103 . A second injection was necessary after a mean period of 5  months.

[Treatment of @entity1103 ( @entity1103 ) with XXXX 0.7mg intravitreal implant].

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetic'] @entity1103 :: ('MESH:D008269', 'Disease') :: ['postoperative cystoid macular edema'] @entity619 :: ('MESH:D003907', 'Chemical') :: ['dexamethasone'] @entity989 :: ('MESH:D012164', 'Disease') :: ['CRT', 'central retinal thickness']
@entity619 :: (MESH:D003907,Chemical) :: ['dexamethasone']
